Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

Menarini Group News

2017 - 06 - 19

Menarini Oncological Research: new investments in Tuscany and Berlin

Logo Menarini Ricerche

Berlin, 19 June 2017 - Menarini has strengthened its commitment to oncological research with new investments in Tuscany and abroad.  Euro for their site in Pisa and 1 million Euro for Berlin are the amounts that will be invested in the company’s respective affiliates. 

Tuscany, the region where Menarini established its Florence headquarters in 1915, will be the first to see the fruits of these new investments in the pharmaceutical sector.

Menarini has been committed to growing its portfolio of oncological projects for several years now. To anticipate the increasing needs of such projects, Menarini has recently made important investments to expand its manufacturing capabilities for oncological drugs by setting up new, dedicated facilities in Pisa (€2 million investment) and Berlin (€1 million investment).

In Pisa, advanced facilities (about 250 m2) have been built for the production of clinical batches of highly potent antitumoral compounds. The new facility will  manufacture both small molecules and biological macromolecules such as antibody-drug conjugates (ADC), obtained through the conjugation of monoclonal antibodies to potent toxins. These new laboratories have been built in compliance with the highest standards of containment for the safety of workers and the environment, and are equipped with last generation reactors, ultrafiltration systems and chromatographic apparatuses. The new facilities will manufacture clinical batches of MEN1309/OBT076. This ADC, which is part of the partnership agreement between Menarini and Oxford Bio Therapeutics (OBT), is being developed for the treatment of solid and hematological tumors.

In the research centre for pharmaceutical development in Berlin, a dedicated building (ca. 230 m2) has been built for packaging, labeling, storage and distribution of clinical trial supplies (CTS) of anti-tumoral compounds, including ADCs. This new facility meets the highest safety standards, is equipped with state of the art systems, and has already received the authorization from the German authority. In the forthcoming months this facility will manufacture and store the CTS for the ADC MEN 1309/OBT076, which will be distributed to clinical trial centers for a first trial on  humans. 

These new achievements are part of the strong commitment of Menarini to oncology with innovative, scientifically advanced and innovative investigational compounds, fully supported by manufacturing capabilities of the highest technological level.